A5077767918- Neuroblastoma Research and Treatments
- Cancer, Hypoxia, and Metabolism
- Cancer therapeutics and mechanisms
- Glioma Diagnosis and Treatment
- Neurofibromatosis and Schwannoma Cases
- Neuroendocrine Tumor Research Advances
- Adrenal and Paraganglionic Tumors
- Lung Cancer Research Studies
- Sarcoma Diagnosis and Treatment
- Childhood Cancer Survivors' Quality of Life
- Chromatin Remodeling and Cancer
- Cell death mechanisms and regulation
- Telomeres, Telomerase, and Senescence
- Mitochondrial Function and Pathology
- Lymphoma Diagnosis and Treatment
- Meningioma and schwannoma management
- Renal and related cancers
- Neonatal Health and Biochemistry
- Cardiac tumors and thrombi
- Virus-based gene therapy research
- Cancer Genomics and Diagnostics
- Ubiquitin and proteasome pathways
- Statistical Methods in Clinical Trials
- Vascular Malformations Diagnosis and Treatment
- Cancer Mechanisms and Therapy
University Hospital Cologne
2016-2025
University of Cologne
2016-2025
Hôpital Saint-Antoine
2023
Sorbonne Université
2023
Assistance Publique – Hôpitaux de Paris
2023
Saarland University
2023
Zentrum für Kinderheilkunde
2014-2022
Klinik und Poliklinik für Kinder- und Jugendmedizin
2005-2022
Seattle Children's Hospital
2015-2020
Baylor College of Medicine
2016
Because current approaches to risk classification and treatment stratification for children with neuroblastoma (NB) vary greatly throughout the world, it is difficult directly compare risk-based clinical trials. The International Neuroblastoma Risk Group (INRG) system was developed establish a consensus approach pretreatment stratification.The statistical significance of 13 potential prognostic factors were analyzed in cohort 8,800 diagnosed NB between 1990 2002 from North America Australia...
The International Neuroblastoma Risk Group (INRG) classification system was developed to establish a consensus approach for pretreatment risk stratification. Because the Staging System (INSS) is postsurgical staging system, new clinical required INRG system.
The excellent prognosis of localized neuroblastoma in infants, the overdiagnosis observed screening studies, and several case reports regression prompted us to initiate a prospective cooperative trial on observation without cytotoxic treatment.For infants with MYCN amplification, chemotherapy was scheduled only cases threatening symptoms; otherwise, tumor either resected or by ultrasound magnetic resonance imaging (MRI).Of 340 eligible participants, 190 underwent resection, 57 were treated...
A systematic look at a childhood tumor Neuroblastomas—the most common type in infants—develop from fetal nerve cells, and their clinical course is highly variable. Some neuroblastomas are fatal despite treatment, whereas others respond well to treatment some undergo spontaneous regression without treatment. Ackermann et al. sequenced more than 400 pretreatment identified molecular features that characterize the three distinct outcomes. Low-risk tumors lack telomere maintenance mechanisms,...
Abstract Whereas aberrant activation of the phosphatidylinositol 3′-kinase (PI3K)/Akt pathway, a key survival cascade, has previously been linked to poor prognosis in several human malignancies, its prognostic effect neuroblastoma not yet explored. We therefore investigated phosphorylation status Akt, S6 ribosomal protein as target mammalian rapamycin, and extracellular signal–regulated kinase (ERK) 116 primary samples by tissue microarray correlation with established markers outcome. Here,...
Purpose Although intensive multimodal treatment has improved the prognosis of patients with metastatic neuroblastoma, impact primary tumor resection on outcome is a matter medical debate. Patients and Methods from German prospective clinical trial NB97 stage 4 neuroblastoma age 18 months or older at diagnosis were included. Operation notes imaging reports reviewed by two independent experienced physicians. Finally, extent resections was correlated local control rate outcome. Results A total...
To evaluate the impact of a predefined gene expression-based classifier for clinical risk estimation and cytotoxic treatment decision making in neuroblastoma patients.Gene expression profiles 440 internationally collected specimens were investigated by microarray analysis, 125 which examined prospectively. Patients classified as either favorable or unfavorable 144-gene prediction analysis microarrays (PAM) established previously on separate set 77 patients. PAM classification results...
The treatment of high-risk neuroblastoma patients consists multimodal induction therapy to achieve remission followed by consolidation prevent relapses. However, the type is still discussed controversial. We applied metronomic chemotherapy in prospective NB90 trial and monoclonal anti-GD2-antibody (MAB) ch14.18 NB97 trial. Here, we present long term outcome data patient cohort. A total 334 stage 4 one year or older were included. All successfully completed therapy. In trial, 99 received at...
Ganglioneuroma (GN) and ganglioneuroblastoma intermixed (GNBI) are mature variants of neuroblastic tumors (NT). It is still discussed whether incomplete resection GN/GNBI impairs the outcome patients. Clinical characteristics localized were retrospectively compared to neuroblastoma (NB) ganglioneuroblastoma-nodular (GNBN) registered in German trials between 2000 2010. Of 808 consecutive NT, 162 (20 %) classified as GN 55 (7 GNBI. patients presented more often with stage 1 disease (68 % vs....
Abstract The clinical course of neuroblastoma is more heterogeneous than any other malignant disease. Most low-risk patients experience regression after limited or even no chemotherapy. However, half high-risk die from disease despite intensive multimodal treatment. Precise patient characterization at diagnosis key for risk-adapted guidelines presented here incorporate results national and international trials to produce recommendations diagnosing treating in German hospitals outside trials.
Abstract The majority of patients with neuroblastoma due to MYCN oncogene amplification and consequent N-Myc oncoprotein over-expression die the disease. Here our analyses RNA sequencing data identify long noncoding lncNB1 as one transcripts most over-expressed in -amplified, compared -non-amplified, human cells also all other cancers. binds ribosomal protein RPL35 enhance E2F1 synthesis, leading DEPDC1B gene transcription. GTPase-activating induces ERK phosphorylation stabilization....
Abstract Background Genomic alterations of the anaplastic lymphoma kinase gene ( ALK ) occur recurrently in neuroblastoma, a pediatric malignancy sympathetic nervous system. However, information on their development over time has remained sparse. Methods were assessed neuroblastomas at diagnosis and/or relapse from total 943 patients, covering all stages disease. Longitudinal diagnostic and relapsed samples individual patients was available 101 102 cases for mutation amplification status,...
PURPOSE Patients with relapsed high-risk neuroblastoma (rHR-NB) have a poor prognosis. We hypothesized that graft-versus-neuroblastoma effects could be elicited by transplantation of haploidentical stem cells (haplo-SCT) exploiting cytotoxic functions natural killer and their activation the anti-GD2 antibody dinutuximab beta (DB). This phase I/II trial assessed safety, feasibility, outcomes immunotherapy DB plus subcutaneous interleukin-2 (scIL2) after haplo-SCT in patients rHR-NB. METHODS...
Antibody treatment is considered tolerable and potentially effective in the therapy of neuroblastoma. We have analyzed stage 4 neuroblastoma patients older than 1 year who underwent consolidation with chimeric monoclonal anti-GD2-antibody ch14.18.Stage completed initial without event were eligible. ch14.18 was scheduled a dose 20 mg/m2/d during 5 days six cycles every 2 months. Patients did not receive served as controls.Of 334 assessable patients, 166 received ch14.18, 99 12-month low-dose...
Abstract Background The prognosis of high‐risk neuroblastoma patients has improved over the last decades. However, many experience relapse after successful initial treatment. We retrospectively analyzed long‐term outcome relapsed three consecutive national trials. Methods Patients were included when they fulfilled all following criteria: Age at diagnosis being 1 year or older, first between 1990 and 2007, stage 4 disease 3 with MYCN amplification, progression first‐line autologous stem cell...
Purpose Radioiodinated metaiodobenzylguanidine ( 123 I-mIBG) scintigraphy is an established imaging method in neuroblastoma. Semiquantitative scoring systems have been developed to assess the extent of disease and response chemotherapy. We present results comparison between SIOPEN [International Society Pediatric Oncology Europe Neuroblastoma Group] score modified Curie score. Patients Methods retrospectively analyzed 147 mIBG scans 58 patients older than 1 year age with stage 4...
Abstract Purpose: To optimize neuroblastoma treatment stratification, we aimed at developing a novel risk estimation system by integrating gene expression–based classification and established prognostic markers. Experimental Design: Gene expression profiles were generated from 709 specimens using customized 4 × 44 K microarrays. Classification models built 75 tumors with contrasting courses of disease. Validation was performed in an independent test set (n = 634) Kaplan–Meier estimates Cox...
Although several studies have been conducted on the role of surgery in localized neuroblastoma, impact surgical timing and extent primary tumor resection outcome high-risk patients remains controversial. Patients from German neuroblastoma trial NB97 with INSS stage 1–3 age > 18 months were included for retrospective analysis. Imaging reports reviewed by two independent physicians Image Defined Risk Factors (IDRF). Operation notes corresponding imaging analyzed radicality. The was classified...